CAR T-cells for the treatment of refractory or relapsed large B-cell lymphoma: A single-center retrospective Canadian study

Last Updated: Friday, June 16, 2023

Researchers compared real-world CAR T-cell infusion efficacy rates for patients with large B-cell lymphoma (LBCL) at their institution with pivotal trials. Bulky disease was found to be the only negative predictor of poor response at 3 months and was associated with a median progression-free survival of 2 months (vs. 5 months for non-bulky disease).

Clinical Lymphoma Myeloma & Leukemia

JAMA Network Open

Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: A meta-analysis

Blood Advances

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy

Blood Advances

Access barriers to anti-CD19+ CAR T-cell therapy for NHL across a community transplant and cellular therapy network

Blood Advances

EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients post CD19-CAR T cell therapy

Blood Advances

Local radiation enhances systemic CAR T cell efficacy by augmenting antigen cross-presentation and T-cell infiltration

Blood Advances

Feasibility and favorable responses following investigational CAR T-Cell therapy for relapsed and refractory infant ALL

Bone Marrow Transplantation

Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: A multicenter study

Frontiers in Immunology

Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: A systematic review and meta-analysis

Blood Advances

Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

Annals of Medicine

Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis

CAR T-Cell Therapy Resource Center

CAR T-cells for the treatment of refractory or relapsed large B-cell lymphoma: A single-center retrospective Canadian study

JAMA Network Open

Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: A meta-analysis

Blood Advances

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy

Blood Advances

Access barriers to anti-CD19+ CAR T-cell therapy for NHL across a community transplant and cellular therapy network

Blood Advances

EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients post CD19-CAR T cell therapy

Blood Advances

Local radiation enhances systemic CAR T cell efficacy by augmenting antigen cross-presentation and T-cell infiltration

Blood Advances

Feasibility and favorable responses following investigational CAR T-Cell therapy for relapsed and refractory infant ALL

Bone Marrow Transplantation

Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: A multicenter study

Frontiers in Immunology

Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: A systematic review and meta-analysis

Blood Advances

Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

Annals of Medicine

Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Fast Facts #12: BCMA Targets